Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05|
- Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up
- Overall survival
- Secondary surgery
- Response rate
- Progression-free survival after the first and the third line of chemotherapy
- Quality of life
|Study Start Date:||February 2002|
|Study Completion Date:||February 2006|
|Primary Completion Date:||February 2006 (Final data collection date for primary outcome measure)|
The addition of oxaliplatin and irinotecan to 5-FU improves tumor response rate and progression-free survival in patients with advanced colorectal cancer compared with 5-FU alone, but increases toxicity. It is not clear whether such combination therapies (5-FU+oxaliplatin or 5-FU+irinotecan) should be systematically used as first line treatment or as second line treatment after 5-FU failure.
Design: open-label, multicentric, randomized trial
Aim: The main objective of this multiline strategy trial was to compare two 5-FU based regimens with or without the addition of oxaliplatin to 5-FU in the first line setting in terms of progression-free survival after two lines of chemotherapy in patients with metastatic colorectal cancer.
Control arm: first line, 2-hour infusion 400 mg/m² leucovorin (LV) followed by 5-fluorouracil 400 mg/m² and 46-hours 2,400 mg/m² every 2 weeks (LV5FU2), second line, LV5FU2 + oxaliplatin 100 mg/m² as a 2-hour perfusion on day 1 (FOLFOX6), third line, LV5FU2 + irinotecan 180 mg/m² (FOLFIRI)
Experimental arm: first line, FOLFOX6, second line, FOLFIRI, third line, 5-FU 250 mg/m²/day in continuous perfusion 7 out of 8 weeks or capecitabine 2,500 mg/m² per oral 14 out of 21 days or inclusion in a phase I
- Histologically confirmed metastatic colorectal adenocarcinoma
- Unresectable metastasis
- Bidimensionally measurable disease (WHO criteria)
- WHO performance status of 2 or less
- Adequate hematologic, renal function and liver functions
- No previous chemotherapy other than previous adjuvant chemotherapy or concomitant chemoradiotherapy with 5-fluorouracil and leucovorin for the treatment of the primary tumor completed at least 6 months before inclusion
- Signed written inform consent
- Quality of life questionnaire (QLQ C-30) filled out
- Pregnant or breast-feeding women
- No possible regular follow-up for psychological, social or geographical reason
- Severe cardiac, respiratory, renal or hepatic failure
- Active coronary heart disease
- Central nervous system metastases
- Past history of second malignancies
- Another investigational drug
- Chronic inflammatory bowel disease
- Previous chemotherapy with irinotecan or oxaliplatin based regimens
Randomization is performed centrally using a minimization technique, stratifying patients according to centre, previous adjuvant treatment, WHO performance status, and number of metastatic sites
Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up.
Overall survival, secondary surgery, response rate, progression-free survival after the first and the third line of chemotherapy, safety, quality of life and costs
Tumor assessments is performed every 8 weeks, quality of live assessment every 8 weeks until progression after 2 lines of chemotherapy or for one year if no progression. After the end of the planned treatment, patients are followed up until death or the cut-off date.
Sample size and statistical analyses:
570 patients, 285 per arm will be needed to detect a difference in median of progression-free survival after two lines of chemotherapy of 3 months from 10 months in the control arm to 13 months in the experimental arm, for a type I error of 5% and a power of 80% (bilateral log rank test).
The analysis will be performed according to the intent-to treat principle. An interim analysis is planned after the inclusion of 400 patients with 3 months follow-up or the occurrence of 250 events and reviewed by an independent data monitoring committee.
Estimated duration of the trial: accrual period, 3 years, minimum follow-up, one year
Please refer to this study by its ClinicalTrials.gov identifier: NCT00126256
|Villejuif, France, 94805|
|Principal Investigator:||Michel Ducreux, Pr||Gustave Roussy, Cancer Campus, Grand Paris|
|Study Director:||Jean-Pierre F Pignon, MD, PhD||Gustave Roussy, Cancer Campus, Grand Paris|